echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Kelun Pharmaceutical Updates TROP-2 ADC Clinical Data and Newly Declares a Class 1 New Drug

    Kelun Pharmaceutical Updates TROP-2 ADC Clinical Data and Newly Declares a Class 1 New Drug

    • Last Update: 2021-09-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On September 26, Kelun Pharmaceutical's TROP-2ADC updated its phase I clinical data in the form of an oral report at the CSCO annual meeting


    The first human trial of SKB264 includes two parts: Phase I dose escalation and Phase II dose expansion


    From: CSCO, official microblog of Kelun Pharmaceutical

    The enrolled patients were patients with locally advanced or metastatic solid tumors who had failed multi-line therapy


    A total of 17 patients received at least one efficacy evaluation, the overall response rate (ORR) was 41.


    From: CSCO, official microblog of Kelun Pharmaceutical

    In terms of safety, all 18 patients reported adverse events (AEs).


    The early clinical research results of SKB264 showed good tolerability, safety and encouraging anti-tumor activity in patients with metastatic solid tumors.


    At the same time, today Kelun has newly declared a new class 1 chemical drug KL290052 capsules.


    From: CDE official website

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.